Does the media favor KROS or RIGL?

In the previous week, Keros Therapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Keros Therapeutics' score of 1.19 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer FTH or KROS?

In the previous week, Keros Therapeutics had 7 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 9 mentions for Keros Therapeutics and 2 mentions for Sensei Biotherapeutics. Keros Therapeutics' average media sentiment score of 1.19 beat Sensei Biotherapeutics' score of 0.96 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PHAR or KROS?

In the previous week, Keros Therapeutics had 5 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Keros Therapeutics and 4 mentions for Pharming Group. Keros Therapeutics' average media sentiment score of 1.19 beat Pharming Group's score of 1.00 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNPR or KROS?

In the previous week, Keros Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Monopar Therapeutics. Keros Therapeutics' average media sentiment score of 1.19 beat Monopar Therapeutics' score of 0.56 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KROS or AURA?

In the previous week, Keros Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Keros Therapeutics' score of 1.19 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Keros Therapeutics (KROS) Competitors

$11.03 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

KROS vs. RIGL, FTH, PHAR, MNPR, and AURA

Should you buy Keros Therapeutics stock or one of its competitors? Keros Therapeutics's main competitors and comparable companies include Rigel Pharmaceuticals (RIGL), Sensei Biotherapeutics (FTH), Pharming Group (PHAR), Monopar Therapeutics (MNPR), and Aura Biosciences (AURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Keros Therapeutics (NASDAQ:KROS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Keros Therapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Keros Therapeutics' score of 1.19 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Rigel Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A
Rigel Pharmaceuticals	$294.28M	2.92	$367.02M	$16.32	2.85

Rigel Pharmaceuticals has a net margin of 116.30% compared to Keros Therapeutics' net margin of -256.60%. Rigel Pharmaceuticals' return on equity of 22.95% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Keros Therapeutics presently has a consensus price target of $20.50, suggesting a potential upside of 85.86%. Rigel Pharmaceuticals has a consensus price target of $59.00, suggesting a potential upside of 26.94%. Given Keros Therapeutics' higher probable upside, equities analysts plainly believe Keros Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rigel Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Keros Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Keros Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Sensei Biotherapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Keros Therapeutics has higher revenue and earnings than Sensei Biotherapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A

In the previous week, Keros Therapeutics had 7 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 9 mentions for Keros Therapeutics and 2 mentions for Sensei Biotherapeutics. Keros Therapeutics' average media sentiment score of 1.19 beat Sensei Biotherapeutics' score of 0.96 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics currently has a consensus price target of $55.00, suggesting a potential upside of 62.53%. Keros Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 85.86%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Keros Therapeutics beats Sensei Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

In the previous week, Keros Therapeutics had 5 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Keros Therapeutics and 4 mentions for Pharming Group. Keros Therapeutics' average media sentiment score of 1.19 beat Pharming Group's score of 1.00 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group currently has a consensus price target of $38.67, indicating a potential upside of 230.48%. Keros Therapeutics has a consensus price target of $20.50, indicating a potential upside of 85.86%. Given Pharming Group's higher possible upside, equities research analysts plainly believe Pharming Group is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Keros Therapeutics has lower revenue, but higher earnings than Pharming Group. Keros Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$366.48M	2.26	$2.85M	$0.12	97.50
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A

Pharming Group has a net margin of 2.51% compared to Keros Therapeutics' net margin of -256.60%. Pharming Group's return on equity of 3.40% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Pharming Group and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Monopar Therapeutics presently has a consensus target price of $118.67, suggesting a potential upside of 6.06%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 85.86%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Keros Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Monopar Therapeutics. Keros Therapeutics' average media sentiment score of 1.19 beat Monopar Therapeutics' score of 0.56 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Keros Therapeutics has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A

Monopar Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Monopar Therapeutics' return on equity of -13.08% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Monopar Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

Summary

Monopar Therapeutics and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Aura Biosciences?

Keros Therapeutics (NASDAQ:KROS) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Aura Biosciences has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Aura Biosciences	N/A	-73.18%	-62.00%

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Keros Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

In the previous week, Keros Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 9 mentions for Keros Therapeutics and 6 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Keros Therapeutics' score of 1.19 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Keros Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 85.86%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 136.49%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Keros Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Summary

Keros Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$218.69M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.98	11.62	273.16	25.42
Price / Sales	0.90	1,380.91	631.89	104.53
Price / Cash	2.44	44.06	28.74	36.03
Price / Book	0.71	16.92	11.08	6.36
Net Income	$87.01M	-$22.74M	$3.48B	$349.79M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	7.93%	9.80%	7.08%	4.13%
1 Year Performance	-27.48%	55.66%	24.67%	15.17%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.6039 of 5 stars	$11.03 flat	$20.50 +85.9%	-27.5%	$218.73M	$244.06M	N/A	100	Positive News Analyst Upgrade
RIGL Rigel Pharmaceuticals	4.547 of 5 stars	$45.25 -3.6%	$59.00 +30.4%	+19.6%	$868.86M	$294.28M	2.77	160	Positive News Analyst Downgrade
FTH Sensei Biotherapeutics	4.2508 of 5 stars	$32.10 -3.1%	$54.90 +71.0%	N/A	$855.58M	N/A	N/A	40
PHAR Pharming Group	3.7303 of 5 stars	$11.68 -1.4%	$38.67 +231.1%	-21.2%	$838.72M	$376.13M	97.33	280
MNPR Monopar Therapeutics	2.0943 of 5 stars	$110.88 -10.5%	$118.67 +7.0%	+227.6%	$831.23M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. RIGL, FTH, PHAR, MNPR, and AURA

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Keros Therapeutics compare to Pharming Group?

Summary

How does Keros Therapeutics compare to Monopar Therapeutics?

Summary

How does Keros Therapeutics compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. RIGL, FTH, PHAR, MNPR, and AURA

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Does the media favor KROS or RIGL?

Which has stronger valuation & earnings, KROS or RIGL?

Is KROS or RIGL more profitable?

Do analysts recommend KROS or RIGL?

Which has more risk and volatility, KROS or RIGL?

Do insiders and institutionals hold more shares of KROS or RIGL?

Summary

How does Keros Therapeutics compare to Sensei Biotherapeutics?

Which has more volatility & risk, FTH or KROS?

Is FTH or KROS more profitable?

Do insiders and institutionals have more ownership in FTH or KROS?

Which has better earnings and valuation, FTH or KROS?

Does the media prefer FTH or KROS?

Do analysts prefer FTH or KROS?

Summary

How does Keros Therapeutics compare to Pharming Group?

Which has more volatility and risk, PHAR or KROS?

Does the media prefer PHAR or KROS?

Do analysts prefer PHAR or KROS?

Which has higher earnings and valuation, PHAR or KROS?

Is PHAR or KROS more profitable?

Do insiders & institutionals believe in PHAR or KROS?

Summary

How does Keros Therapeutics compare to Monopar Therapeutics?

Do analysts prefer MNPR or KROS?

Does the media favor MNPR or KROS?

Which has stronger earnings and valuation, MNPR or KROS?

Is MNPR or KROS more profitable?

Do insiders and institutionals hold more shares of MNPR or KROS?

Which has more volatility & risk, MNPR or KROS?

Summary

How does Keros Therapeutics compare to Aura Biosciences?

Is KROS or AURA more profitable?

Do institutionals and insiders believe in KROS or AURA?

Which has higher earnings and valuation, KROS or AURA?

Does the media favor KROS or AURA?

Do analysts rate KROS or AURA?

Which has more volatility and risk, KROS or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools